CDK4 and non-small cell lung carcinoma: Abemaciclib inhibited IR-induced DNA damage repair and caused RB-dependent cell cycle arrest; furthermore, the study identified possible predictive biomarkers (p53, RB, and SDF-1) to guide the efficacy and efficacy of the combination therapy, emphasized that CDK4/6 axis is a potential radiation target for NSCLC and warranting the value of abemaciclib as a radiation modifier in clinical trials (49).